tirzepatide 1.5 mg Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Tirzepatide Dosing - A Patient

While initially used for diabetes and obesity management, GLP-1 agonists are now being explored as a treatment for liver diseases like MASH, due to their positive effects on metabolic health

Combining them does not necessarily create synergistic fat loss

Metabolic dysfunctionassociated steatotic liver disease

Randomized trials have shown that liraglutide and semaglutide can improve walking distance in people with PAD, while observational studies have linked semaglutide and tirzepatide to lower risks of amputation, lower-extremity revascularization, and mortality

Most gastrointestinal side effects occur during dose escalation and typically resolve within 4-8 weeks